EPS

Revised forecasts again appear to be too conservative given prevailing spot and futures prices.

• Read more

S&P 500 valuations using corporate profits (National Income Accounts), not as cheap as suggested and are likely faulty, in our opinion.

• Read more

Conceptually we think that the big drug stocks are poised to rebound, but they have yet to rank Attractive in the Group Selection Scores.

• Read more

We applauded S&P for developing a standardized approach which adjusts GAAP earnings for several problem accounting areas and produces a better representation of “True” earnings.

• Read more